Research programme: cystic fibrosis therapy - Cystic Fibrosis Foundation/SGX Pharmaceuticals
Latest Information Update: 09 Sep 2010
At a glance
- Originator Cystic Fibrosis Foundation Therapeutics; SGX Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 20 Aug 2008 SGX Pharmaceuticals has been acquired by Eli Lilly and Company
- 04 Feb 2008 Preclinical development is ongoing
- 31 Aug 2005 Structural GenomiX is now called SGX Pharmaceuticals